Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
HCC1806 | Dinaciclib | pan CDK | Cell cycle | 0.013395 | -0.4585 | 0.6439 | 0.3114 | 3.4710 | 0.016174 | 0.99891 |
PDX1258 | Topotecan | Topo I | Chemotherapy | 0.013472 | -0.4565 | 0.8673 | 0.2817 | 0.8122 | 0.026852 | 0.98013 |
HCC1500 | Dinaciclib | pan CDK | Cell cycle | 0.013792 | -0.5720 | 0.6616 | 0.1978 | 2.3762 | 0.018927 | 0.99749 |
HCC1954 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.014251 | -0.0830 | 0.5651 | 0.1455 | 1.3479 | 0.013876 | 0.98856 |
MDA-MB-436 | Dinaciclib | pan CDK | Cell cycle | 0.014324 | -0.1440 | 0.4903 | 0.0235 | 4.8527 | 0.014993 | 0.99777 |
SUM159PT | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.014492 | 0.1057 | 0.4137 | 0.0050 | 1.4641 | 0.011782 | 0.9977 |
HCC1395 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.014555 | -0.1424 | 0.4547 | 0.0604 | 1.6344 | 0.015746 | 0.98865 |
CAMA-1 | Dinaciclib | pan CDK | Cell cycle | 0.014558 | -0.4849 | 0.6062 | 0.1927 | 2.0283 | 0.019954 | 0.99839 |
CAL-51 | Dinaciclib | pan CDK | Cell cycle | 0.014709 | -0.3585 | 0.5985 | 0.2374 | 3.5319 | 0.017105 | 0.99939 |
PDX1258 | AZD7762 | CHK1/2 | Cell cycle | 0.014946 | -0.4528 | 0.9199 | 0.3234 | 1.6838 | 0.021221 | 0.99249 |
CAL-51 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.014971 | 0.0529 | 0.5532 | 0.1010 | 0.9663 | 0.012822 | 0.99761 |
SUM1315MO2 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.015037 | -0.0903 | 0.4863 | 0.0621 | 0.7079 | 0.022637 | 0.99665 |
Hs 578T | AZD7762 | CHK1/2 | Cell cycle | 0.015096 | -0.5983 | 0.8646 | 0.4133 | 1.8783 | 0.01967 | 0.95944 |
HCC1143 | Dinaciclib | pan CDK | Cell cycle | 0.015148 | -0.2527 | 0.5451 | 0.1106 | 5.0000 | 0.016398 | 0.9989 |
MDA-MB-157 | AZD7762 | CHK1/2 | Cell cycle | 0.015418 | -0.7858 | 0.9840 | 0.3122 | 0.8223 | 0.045445 | 0.98837 |
HCC1937 | Topotecan | Topo I | Chemotherapy | 0.0155 | -0.4282 | 0.8369 | 0.2949 | 0.6712 | 0.03544 | 0.94323 |
MDA-MB-468 | Dinaciclib | pan CDK | Cell cycle | 0.015576 | -0.4131 | 0.5681 | 0.1843 | 2.8840 | 0.018635 | 0.99641 |
CAL-85-1 | Topotecan | Topo I | Chemotherapy | 0.015768 | -0.2957 | 0.8426 | 0.2732 | 1.2311 | 0.02233 | 0.99293 |
MDA-MB-468 | Topotecan | Topo I | Chemotherapy | 0.015779 | -0.6577 | 1.0692 | 0.4464 | 2.1036 | 0.023029 | 0.99528 |
HCC1806 | Doxorubicin | Chemo | Chemotherapy | 0.015898 | -0.3241 | 0.6281 | 0.1971 | 1.0948 | 0.021206 | 0.97525 |
MDA-MB-468 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.016032 | -0.0415 | 0.4371 | 0.1010 | 0.9482 | 0.015849 | 0.98843 |
MCF7 | Doxorubicin | Chemo | Chemotherapy | 0.016105 | -0.2856 | 0.6363 | 0.1012 | 0.9326 | 0.024539 | 0.97476 |
MCF 10A | Dinaciclib | pan CDK | Cell cycle | 0.016244 | -0.2300 | 0.5279 | 0.2344 | 5.0000 | 0.017523 | 0.99904 |
HCC1500 | Doxorubicin | Chemo | Chemotherapy | 0.016258 | -0.7134 | 0.7518 | 0.1833 | 0.7212 | 0.058468 | 0.98572 |
SK-BR-3 | Topotecan | Topo I | Chemotherapy | 0.016549 | -0.2711 | 0.7941 | 0.1919 | 1.9350 | 0.01923 | 0.98214 |